Company profilePharmaceutical#233 of 1,318 in Pakistan3 DRAP alerts

Bajwa Pharmaceuticals (Pvt.) Ltd.

Pharmaceutical company · 78 brands · 88 molecules

Ranked #2 of 36 companies in Cardiac Therapy

78 registered products 34 pharmaceutical brands 88 distinct molecules 3 DRAP alerts

Company overview

78
registered products
34
pharmaceutical brands
88
distinct molecules
12
therapeutic classes
3
DRAP alerts

Bajwa Pharmaceuticals (Pvt.) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 78 product registrations across 88 distinct molecules. Its portfolio is concentrated in Cardiac Therapy and Other Nervous System Drugs. DRAP has issued 3 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Bajwa

45 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

43
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202643

Top molecules by brand count

Amikacin5 brands
Bupivacaine5 brands
Ketamine4 brands
Atracurium2 brands
Neostigmine2 brands
Amiodarone2 brands
Ketamine ...... 50Mg2 brands
Ephedrine2 brands

Therapeutic classes

Cardiac Therapy · 6Other Nervous System Drugs · 3Anaesthetic, Local · 3Anaesthetic, General · 3Antiemetics & Antinauseants · 2Opioids · 2Antiinflammatory And Antirheumatic Products · 2Beta Blocking Agent · 2Diagnostic Agents · 2Vitamin B12 Plain · 2Other Cardiac Preparations · 1Pain Management · 1

Conditions treated

Muscle Relaxant/Spasm · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official104 products · Rs 3.93 – Rs 6,204.77
DVAGO1 products · Rs 190 – Rs 190
Servaid1 products · Rs 614.6 – Rs 614.6
Median across source: Rs 208.46

Regulatory record

3 alerts in the DRAP feed we track.

107. Recall Alert – (Class-I) Injection Isobaj (Batch # IB-0925)
2025-11-12
Recall Alert: Recall of Adulterated Synostat Injection Batch No. Ss-0624 Manufactured by M
2025-01-13
Drug Safety Alert: Risks associated with the use of Valproic Acid in Women and Girls of Ch
2024-05-10

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

NEUTRO PHARMA (PVT) LTD. holds 118 molecules not in this portfolio
AcetylcysteineAcyclovirAlbendazoleAnastrazoleAnastrozoleAntimony
Elite Pharma (Pvt) Ltd holds 16 molecules not in this portfolio
000 I.UAdrenalineAdrenaline BpAmoxicillinAntipyretic)Cefixime
SURGE LABORATORIES (PVT) LTD. holds 36 molecules not in this portfolio
ArtemetherArtesunateAtropine InjAtropine UspCefiximeCefotaxime

Get the full profile for Bajwa

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.